Is medicinal ketamine associated with urinary dysfunction issues? Assessment of both the European Medicines Agency (EMA) and the UK Yellow Card Scheme pharmacovigilance database-related reports.

Nicolo' SchifanoStefania ChiappiniFabio CastiglioneAndrea SaloniaFabrizio Schifano

Published in: Lower urinary tract symptoms (2020)

Current data may only represent a gross underestimate of the KIU real prevalence issues. It is here suggested that chronic treatment involving higher doses/repeated exposure to ketamine be restricted to the context of controlled trials or clinical audits.

Keyphrases

adverse drug
pain management
electronic health record
drug induced
risk factors
oxidative stress
big data
emergency department
machine learning
data analysis